Workflow
CNS Pharmaceuticals(CNSP) - 2023 Q4 - Annual Results

Filing Information This section details the registrant's identification, incorporation jurisdiction, emerging growth status, and registered securities Registrant and Filing Details This section provides the basic identification details for CNS Pharmaceuticals, Inc. as the registrant, including its address, jurisdiction, and confirmation of its status as an emerging growth company - Registrant: CNS Pharmaceuticals, Inc.1 - Jurisdiction of Incorporation: Nevada1 - Emerging Growth Company Status: Yes3 Securities Registered The company's common stock is registered on The NASDAQ Stock Market LLC under the trading symbol CNSP | Title of each class | Trading Symbols(s) | Name of each exchange on which registered | | :------------------ | :----------------- | :---------------------------------------- | | Common stock, par value $0.001 per share | CNSP | The NASDAQ Stock Market LLC | Item 2.02 Results of Operations and Financial Condition CNS Pharmaceuticals, Inc. announced its financial results for the period ended December 31, 2023, and recent operational highlights through a press release issued on April 1, 2024. This press release is incorporated by reference as Exhibit 99.1 - Company issued a press release on April 1, 2024, announcing financial results for the period ended December 31, 2023, and recent operational highlights5 - The press release is attached to this report as Exhibit 99.1 and is incorporated by reference5 Item 9.01 Financial Statements and Exhibits This section details the financial statements and exhibits filed with the report, including the press release and interactive data file Exhibits List This section lists the exhibits filed with the Form 8-K, including the press release detailing financial results and the interactive data file | Exhibit No. | Exhibit Description | | :------------ | :---------------------------------------------------------- | | 99.1 | Press release dated April 1, 2024 | | 104 | Cover page Interactive Data File (embedded within the Inline XBRL document) | Signature The report was duly signed on behalf of CNS Pharmaceuticals, Inc. by Chris Downs, Chief Financial Officer, on April 1, 2024, in accordance with the Securities Exchange Act of 1934 requirements - Report signed by Chris Downs, Chief Financial Officer of CNS Pharmaceuticals, Inc.10 - Date of signature: April 1, 202410